Micro-Iboga/Casa-Well is an information platform and community which provides harm reduction and education regarding Iboga microdosing. We do not endorse the use of psychedelic substances, nor encourage anyone to engage in illegal activities. We are not medical practitioners nor offer any medical advice. We do not claim that microdosing is clinically proven as an effective medicine, medicinal aid or supplement.

No aid in sourcing Iboga
The legal status of Iboga varies widely from country to country, and sometimes from state to state. We urge you to always abide by the laws and regulations of the country, state, county, and city you live in. Micro-Iboga/Casa-Well does NOT provide Iboga, neither do we provide sourcing references or points of sale for jurisdictions where the selling and/or consumption of Iboga is illegal.
No medical advice

Micro-Iboga/Casa-Well does not provide medical advice. Information provided through this program can therefore not be considered a substitute for a consultation or treatment by a physician. Therefore, Micro-Iboga/Casa-Well cannot accept liability for any damage resulting from the use of the information on this site, or from starting, changing, stopping or adapting any treatment without medical advice.

Responsible Engagement with Iboga Microdosing

Our programs provide harm reduction information regarding the responsible engagement with Iboga microdosing. Anyone participating in our programs will be assumed to be engaging responsible with the psychedelic medicine, which we define as follows:
Awareness of and Reduction of Potential Risks and Side Effects
Like most pharmacological medicines, Microdosing Iboga for extended periods of time carries potential risks. However, by following some simple guidelines these risks can be minimized.

Cardiovascular risks: The primary cardiovascular risk associated with consuming Iboga or its derivatives is the potential prolongation of the QT interval, which could result in cardiac arrest.While there is enough evidence to suggest that microdosing Iboga does not pose cardiovascular risks for individuals without underlying cardiovascular conditions, the long-term cardiovascular safety of microdosing Iboga has not been definitively proven through clinical studies.

Therefore, although there is sufficient pre-clinical evidence supporting the safety of Iboga microdosing in a 12-week cycle, we advise limiting microdosing to an 8-week cycle unless under the guidance of an experienced professional in Iboga microdosing.

Psychological risks and symptoms:
Microdosing Iboga carries a comparable psychological risk to other microdosing medicines. For individuals without significant psychiatric disorders, the risk is minimal, involving potential temporary increases in anxiety, emotional overwhelm, and sleep disturbances. Conversely, microdosing Iboga, like any other psychedelic, can worsen the condition for those with a history of psychosis or personality disorders.

Risks due to other underlying conditions:
Many neurological issues which may benefit from ibogaine treatment may also end up causing dangerous contraindications. For example, although many people with TBI may benefit from ibogaine therapy, there is no one- size-fits-all TBI and there could be an increased risk of seizures due to neurotransmitter level changes caused by ibogaine.
Active benzodiazepine withdrawals are absolutely contraindicated due to increased risk of seizure.
Epilepsy is contraindicated, for the same reason.
There is evidence that ibogaine and its metabolites have some hepatotoxicity. People with liver damage may be harmed by Iboga microdosing.

Potential Side Effects:
Increased Anxiety and Emotional Disturbances: Some of Iboga's valuable effects may lead to emotional overwhelm. Proper microdosing guidance can minimize these risks. However, it's crucial to be adequately prepared for such situations. We'll cover this more thoroughly in the "Preparations" slideshow.
Sleep Disturbances: Microdosing Iboga, similar to coffee, can provide an invigorating and energizing effect. However, taking it too late in the day or at a high dose may result in sleeplessness.

Dose Build-Up: If calibrated improperly, Iboga microdosing can cause the accumulation of noribogaine in the body , leading to high dose experiences.
Awareness of Contraindications and Commitment to Avoiding Contraindicated Substances
The following substances must be strictly avoided for the duration of an Iboga microdosing protocol:
Cocaine
Kratom
Methamphetamines and Amphetamines, including: Adderall®, Concerta®, Dexedrine®, Focalin®, Metadate®, Methylin®, Ritalin®. Also including methamphetamine.
The following substances must be strictly avoided 4 days before, during the program, and 2 weeks after:
MAO-Inhibitors (Ayahuasca)
MDMA (also MDA, MDEA, etc)
Opioids
All research chemicals
Commitment to maintaining a responsible protocol for self and others
Consult a medical provider if you feel seriously ill or impaired due to the microdosing protocol.
Refrain from harming yourself by taking a large dose of Iboga without the appropriate guidance and accompaniment. Consuming a larger dose of Iboga is a serious endeavor that requires expert psychological and medical accompaniment and guidance.
Refrain from harming others by offering medicine to people who have not been properly screened, or who are, in any other way, not prepared to engage in a responsible Iboga microdosing protocol.
Refrain from harming others by offering advice or expertise regarding Iboga microdosing that you do not have.